BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 22260032)

  • 1. [Pharmacokinetics of cantide, an antisense oligonucleotide, and its metabolites in rhesus monkeys].
    Wang XZ; Wang SH; Song HF; Wang QQ; Wang SQ
    Yao Xue Xue Bao; 2011 Nov; 46(11):1370-3. PubMed ID: 22260032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Quantitative determination of Cantide, an antisense oligodeoxynucleotide in rhesus monkey plasma using non-gel sieving capillary electrophoresis method].
    Wang X; Wang Q; Wang S; Li W; Song H; Lu D; Wang S
    Se Pu; 2010 Jun; 28(6):561-5. PubMed ID: 20873576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Determination of antisense phosphorothioate oligonucleotide drug Cantide by capillary gel electrophoresis].
    Yang B; Sun O; Zhang M; Wang S
    Se Pu; 2004 May; 22(3):202-5. PubMed ID: 15712897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Quantitative analysis of cantide in plasma by capillary gel electrophoresis].
    Zhang W; Yang B; Liang Q; Lu D; Lin R; Wang S
    Se Pu; 2005 Jul; 23(4):374-7. PubMed ID: 16250446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression.
    Geary RS; Leeds JM; Fitchett J; Burckin T; Truong L; Spainhour C; Creek M; Levin AA
    Drug Metab Dispos; 1997 Nov; 25(11):1272-81. PubMed ID: 9351904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in Monkeys.
    Yu RZ; Gunawan R; Post N; Zanardi T; Hall S; Burkey J; Kim TW; Graham MJ; Prakash TP; Seth PP; Swayze EE; Geary RS; Henry SP; Wang Y
    Nucleic Acid Ther; 2016 Dec; 26(6):372-380. PubMed ID: 27500733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species.
    Geary RS; Yu RZ; Watanabe T; Henry SP; Hardee GE; Chappell A; Matson J; Sasmor H; Cummins L; Levin AA
    Drug Metab Dispos; 2003 Nov; 31(11):1419-28. PubMed ID: 14570775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A nonradioisotope biomedical assay for intact oligonucleotide and its chain-shortened metabolites used for determination of exposure and elimination half-life of antisense drugs in tissue.
    Geary RS; Matson J; Levin AA
    Anal Biochem; 1999 Oct; 274(2):241-8. PubMed ID: 10527522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and metabolism of an oligodeoxynucleotide phosphorothioate (GEM91) in cynomolgus monkeys following intravenous infusion.
    Grindel JM; Musick TJ; Jiang Z; Roskey A; Agrawal S
    Antisense Nucleic Acid Drug Dev; 1998 Feb; 8(1):43-52. PubMed ID: 9512095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of tumor growth and metastasis with antisense oligonucleotides (Cantide) targeting hTERT in an in situ human hepatocellular carcinoma model.
    Lin RX; Tuo CW; Lü QJ; Zhang W; Wang SQ
    Acta Pharmacol Sin; 2005 Jun; 26(6):762-8. PubMed ID: 15916744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers.
    Fornasini G; Monti N; Brogin G; Gallina M; Eandi M; Persiani S; Bani M; Della Pepa C; Zara G; Strolin Benedetti M
    Chirality; 1997; 9(3):297-302. PubMed ID: 9176996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors.
    Chen HX; Marshall JL; Ness E; Martin RR; Dvorchik B; Rizvi N; Marquis J; McKinlay M; Dahut W; Hawkins MJ
    Clin Cancer Res; 2000 Apr; 6(4):1259-66. PubMed ID: 10778949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and tissue disposition in monkeys of an antisense oligonucleotide inhibitor of Ha-ras encapsulated in stealth liposomes.
    Yu RZ; Geary RS; Leeds JM; Watanabe T; Fitchett JR; Matson JE; Mehta R; Hardee GR; Templin MV; Huang K; Newman MS; Quinn Y; Uster P; Zhu G; Working PK; Horner M; Nelson J; Levin AA
    Pharm Res; 1999 Aug; 16(8):1309-15. PubMed ID: 10468036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue disposition of 2'-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys.
    Yu RZ; Geary RS; Monteith DK; Matson J; Truong L; Fitchett J; Levin AA
    J Pharm Sci; 2004 Jan; 93(1):48-59. PubMed ID: 14648635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice.
    Raynaud FI; Orr RM; Goddard PM; Lacey HA; Lancashire H; Judson IR; Beck T; Bryan B; Cotter FE
    J Pharmacol Exp Ther; 1997 Apr; 281(1):420-7. PubMed ID: 9103525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100.
    Yu RZ; Kim TW; Hong A; Watanabe TA; Gaus HJ; Geary RS
    Drug Metab Dispos; 2007 Mar; 35(3):460-8. PubMed ID: 17172312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model.
    Berg SL; Reid J; Godwin K; Murry DJ; Poplack DG; Balis FM; Ames MM
    J Pediatr Hematol Oncol; 1999; 21(1):26-30. PubMed ID: 10029808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of ISIS 104838, a 2'-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha.
    Sewell KL; Geary RS; Baker BF; Glover JM; Mant TG; Yu RZ; Tami JA; Dorr FA
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1334-43. PubMed ID: 12438559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of His-tag recombinant human endostatin in Rhesus monkeys.
    Song HF; Liu XW; Zhang HN; Zhu BZ; Yuan SJ; Liu SY; Tang ZM
    Acta Pharmacol Sin; 2005 Jan; 26(1):124-8. PubMed ID: 15659125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice.
    Yu RZ; Zhang H; Geary RS; Graham M; Masarjian L; Lemonidis K; Crooke R; Dean NM; Levin AA
    J Pharmacol Exp Ther; 2001 Feb; 296(2):388-95. PubMed ID: 11160622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.